|
1
|
Kitamura K, Kangawa K, Kawamoto M, et al:
Adrenomedullin: A novel hypotensive peptide isolated from human
pheochromocytoma. Biochem Biophys Res Commun. 192:553–560. 1993.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hay DL, Walker CS and Poyner DR:
Adrenomedullin and calcitonin gene-related peptide receptors in
endocrine-related cancers: Opportunities and challenges. Endocr
Relat Cancer. 18:C1–C14. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Beltowski J and Jamroz A: Adrenomedullin -
what do we know 10 years since its discovery? Pol J Pharmacol.
56:5–27. 2004.PubMed/NCBI
|
|
4
|
Eto T: A review of the biological
properties and clinical implications of adrenomedullin and
proadrenomedullin N-terminal 20 peptide (PAMP), hypotensive and
vasodilating peptides. Peptides. 22:1693–1711. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kato J, Kitamura K, Matsui E, et al:
Plasma adrenomedullin and natriuretic peptides in patients with
essential or malignant hypertension. Hypertens Res. 22:61–65. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ishimitsu T, Ono H, Minami J and Matsuoka
H: Pathophysiologic and therapeutic implications of adrenomedullin
in cardiovascular disorders. Pharmacol Ther. 111:909–927. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Li Y, Jiang C, Wang X, Zhang Y, Shibahara
S and Takahashi K: Adrenomedullin is a novel adipokine:
Adrenomedullin in adipocytes and adipose tissues. Peptides.
28:1129–1143. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lainchbury JG, Troughton RW, Lewis LK,
Yandle TG, Richards AM and Nicholls MG: Hemodynamic, hormonal and
renal effects of short-term adrenomedullin infusion in healthy
volunteers. J Clin Endocrinol Metab. 85:1016–1020. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Szokodi I, Kinnunen P and Ruskoaho H:
Inotropic effect of adrenomedullin in the isolated perfused rat
heart. Acta Physiol Scand. 156:151–152. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Federico C: Natriuretic Peptide system and
cardiovascular disease. Heart Views. 11:10–15. 2010.PubMed/NCBI
|
|
11
|
Kitamura K and Eto T: Adrenomedullin -
physiological regulator of the cardiovascular system or biochemical
curiosity? Curr Opin Nephrol Hypertens. 6:80–87. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Herget-Rosenthal S, Bökenkamp A and
Hofmann W: How to estimate GFR-serum creatinine, serum cystatin C
or equations? Clin Biochem. 40:153–161. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Whitworth JA; World Health Organiztion, ;
International Society of Hypertension Writing Group, : 2003 World
Health Organization (WHO)/International Society of Hypertension
(ISH) statement on management of hypertension. J Hypertens.
21:1983–1992. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kitamura K, Ichiki Y, Tanaka M, et al:
Immunoreactive adrenomedullin in human plasma. FEBS Lett.
341:288–290. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wang Y, Zhou Y, Meng L, Lu X, Ou N and Li
X: Inflammatory mediators in Chinese patients with congestive heart
failure. J Clin Pharmacol. 49:591–599. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Cheung BM and Tang F: Adrenomedullin:
Exciting new horizons. Recent Pat Endocr Metab Immune Drug Discov.
6:4–17. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Suzuki Y, Horio T, Hayashi T, et al:
Plasma adrenomedullin concentration is increased in patients with
peripheral arterial occlusive disease associated with vascular
inflammation. Regul Pept. 118:99–104. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kato J, Kitamura K and Eto T: Plasma
adrenomedullin level and development of hypertension. J Hum
Hypertens. 20:566–570. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kato J, Tsuruda T, Kita T, Kitamura K and
Eto T: Adrenomedullin: A protective factor for blood vessels.
Arterioscler Thromb Vasc Biol. 25:2480–2487. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Tsuruda T, Kato J, Hatakeyama K, et al:
Antifibrotic effect of adrenomedullin on coronary adventitia in
angiotensin II-induced hypertensive rats. Cardiovasc Res.
65:921–929. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Irzmański R, Pawlicki L, Charłusz M and
Kowalski J: Concentration of natriuretic peptides in patients
suffering from idiopathic arterial hypertension and left
ventricular diastolic dysfunction confirmed by echocardiography.
Clin Exp Hypertens. 34:530–540. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kohno M, Hanehira T, Kano H, et al: Plasma
adrenomedullin concentrations in essential hypertension.
Hypertension. 27:102–107. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kong DG, Gao H, Lu YQ, et al: Anxiety
disorders are associated with increased plasma adrenomedullin level
and left ventricular hypertrophy in patients with hypertension.
Clin Exp Hypertens. 36:27–31. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Grzywa-Celińska A, Celiński R, Kwaśniewska
K, Dyczko M, Prystupa A and Mosiewicz J: The usefulness of
natriuretic peptides measurements in the diagnostics of chosen
cardiovascular diseases. Pol Merkur Lekarski. 34:232–234.
2013.PubMed/NCBI
|
|
25
|
Halawa B: Plasma adrenomedullin
concentration in patients with essential hypertension. Pol Merkur
Lekarski. 5:111–113. 1998.PubMed/NCBI
|
